Evidence map›Paper›PMID 40500502›Full record

ReviewAdvances in neurobiology2025

Role of Oligodendrocyte Lineage Cells in White Matter Injury.

Katarzyna Pieczonka, Oliver Zhang, Sogolie Kouhzaei, Alexander A Velumian, Michael G Fehlings

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Katarzyna PieczonkaKrembil Research Institute, University Health Network, Toronto, ON, Canada.
Oliver ZhangKrembil Research Institute, University Health Network, Toronto, ON, Canada.
Sogolie KouhzaeiKrembil Research Institute, University Health Network, Toronto, ON, Canada.
Alexander A VelumianKrembil Research Institute, University Health Network, Toronto, ON, Canada.
Michael G FehlingsKrembil Research Institute, University Health Network, Toronto, ON, Canada. Michael.Fehlings@uhn.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This chapter provides a comprehensive review of white matter injuries, with a particular focus on oligodendrocyte lineage cell-mediated mechanisms and strategies. Traumatic mechanical insults, vascular conditions, perinatal injuries, and degenerative diseases all have white matter components and can be studied using different animal models. These distinct etiologies converge on similar pathophysiological features comprised of programmed cell death of oligodendrocyte lineage cells, demyelination, release of myelin debris, ion imbalance, excitotoxicity, mitochondrial dysfunction, and Wallerian degeneration. Therapeutics that target oligodendrocyte lineage cells are warranted due to their role in remyelination, immunomodulation, circuit remodeling, and maintenance of vasculature. Thus, emerging diagnostic techniques can help in assessing the extent of oligodendrocyte lineage cell-related pathology, while regenerative treatments, including cell transplantation, endogenous cell mobilization, biomaterials, and rehabilitation, can facilitate recovery by driving regeneration of oligodendrocyte lineage cells and myelin. Despite tremendous progress in this field, the heterogeneity of oligodendrocyte lineage cells suggests that a personalized medicine approach may optimize recovery following injury.

Indexed as

Cell LineageOligodendrogliaWhite MatterAnimalsHumansBrainDiagnosticsMyelinOligodendrocyteOligodendrocyte lineage cellOligodendrocyte progenitor cellPathophysiologyRegenerative medicineSpinal cordWhite matter injury

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.